

The Global Point Prevalence Survey (Global-PPS): quality indicators for antimicrobial use for adult patients in the Philippines 2017-2023

Jemelyn U. Garcia¹, Mari Rose A. De Los Reyes¹, Ann Versporten², Ines Pauwels², Rhenalyn Bo¹, Regina P. Berba³, Ma Charmian Hufano⁴, Erika Vlieghe^{2,5}

¹Research Institute for Tropical Medicine - Muntinlupa City (Philippines), ²University of Antwerp - Antwerp (Belgium), ³Philippine General Hospital - Manila (Philippines), ⁴De Los Santos Medical Center - Quezon City (Philippines), ⁵University Hospital Antwerp -Antwerp (Belgium)

BACKGROUND & OBJECTIVES

Assessment of the quality of antimicrobial prescriptions is essential for monitoring an antimicrobial stewardship program. This study aims to evaluate a set of quality indicators over a sevenyear period and to identify areas for improvement in antibiotic use in the Philippine setting.

METHODS

The Global-PPS is a cross-sectional survey on the prevalence of antimicrobial use among admitted patients in the hospital. It was conducted in the Philippines from 2017-2023. The survey included all inpatients receiving an antimicrobial on the day of the survey. Data collected included details on the antimicrobial agents, indications for treatment and antimicrobial prophylaxis as well as a set of quality indicators. A web-based application designed by the University of Antwerp was used for data entry, validation, and reporting, (www.global-pps.com).

RESULTS

Table 1. Top 10 most commonly used antibiotics (% of J01 prescriptions) in adult wards

2019 2020 2021 2017 2018 2022 2023 (n=4,111) (n=5,546) (n=5,247) (n=8,791) (n=12,804) (n=3,439) (n=11,224) Cefuroxime 17.3 Cefuroxime 16.7 Cefuroxime 13.9 Ceftriaxone 11.3 Ceftriaxone 13.8 Ceftriaxone 13.8 Ceftriaxone 15.6 Piperacillin and Piperacillin and 10.0 Ceftriaxone 10.8 Ceftriaxone Cefuroxime 11.6 Cefuroxime 11.8 12.1 Ceftriaxone 11.9 11.0 enzvme inhibitor enzyme inhibitor Piperacillin and Piperacillin and Piperacillin and Piperacillin and Piperacillin and 8.2 Cefuroxime 11.0 9.9 Cefuroxime 11.0 11.2 11.3 8.8 enzyme inhibitor enzyme inhibitor enzyme inhibitor enzyme inhibitor enzyme inhibitor Azithromycin 8.3 Azithromycin 6.7 Azithromycin Azithromycin 5.8 7.4 Azithromycin Meropenem 6.4 Azithromycin 6.4 9.2 5.7 Clindamycin 5.3 Clindamycin 6.1 Clindamycin Clindamycin 5.0 Meropenem 7.2 Meropenem 6.5 Azithromycin 6.0 Ampicillin and 4.2 4.3 5.8 5.7 Metronidazole 5.1 Meropenem 4.5 Metronidazole 5.0 Clindamycin Clindamycin Meropenem enzyme inhibitor 4.7 5.1 Metronidazole 3.9 4.5 Clindamycin 5.0 Levofloxacin 4.0 Metronidazole 4.6 Metronidazole Meropenem Meropenem 3.5 3.4 3.8 Metronidazole 4.1 Ciprofloxacin 3.8 Vancomycin Cefazolin Cefazolin Levofloxacin 4.0 3.5 Vancomycin 3.3 3.8 3.4 Ciprofloxacin 3.5 Cefazolin 3.4 Cefazolin Cefazolin Ciprofloxacin 4.0 Vancomycin 3.2 Metronidazole Ampicillin and Ampicillin and Ampicillin and 3.3 3.1 3.5 Levofloxacin Ceftazidime Levofloxacin 3.2 3.4 3.0 3.0 Levofloxacin enzyme inhibitor enzyme inhibitor enzyme inhibitor

Table 2. Top 5 diagnoses for therapeutic antimicrobial treatment (% of patients on antimicrobials) in adult wards

2017 (n=1,736 patients)			2018 (n=2,608 patients)			2019 (n=2,518 patients)			2020 (n=1,852 patients)			2021 (n=4,881 patients)			2022 (n=5,515 patients)			2023 (n=6,361 patients)		
	N	%	//	N	%		Ν	%		N	%		N	%		N	%		N	%
Pneumonia	717	41.3	Pneumonia	1065	40.8	Pneumonia	1129	44.8	Pneumonia	810	43.7	Pneumonia	2273	46.6	Pneumonia	2297	41.7	Pneumonia	2635	41.4
Skin and soft tissue infections	277	16.0	Skin and soft tissue infections	406	15.6	Skin and soft tissue infections	322	12.8	Skin and soft tissue infections	269	14.5	COVID-19	833	17.1	Skin and soft tissue infections	915	16.6	Skin and soft tissue infections	1010	15.9
Gastrointesti nal infections	135	7.8	Gastrointesti nal infections	156	6.0	Intra- abdominal infections	166	6.6	Intra- abdominal infections	151	8.2	Skin and soft tissue infections	447	9.2	Gastrointesti nal infections	334	6.1	Gastrointesti nal infections	414	6.5
Lower urinary tract infections	96	5.5	Lower urinary tract infections	154	5.9	Lower urinary tract infections	147	5.8	Sepsis	104	5.6	Obstetric/gy necological infections	262	5.4	Lower urinary tract infections	334	6.1	Lower urinary tract infections	394	6.2
Intra- abdominal infections	101	5.8	Upper urinary tract infections	153	5.9	Tuberculosis	145	5.8	Lower urinary tract infections	90	4.9	Lower urinary tract infections	221	4.5	Tuberculosis	312	5.7	Tuberculosis	359	5.6

Data were collected from 72 hospitals in 2018:28, Philippines (2017:16, the 2019:31, 2020:34, 2021:50, 2022:57, 2023:61). A total of 71,659 patients on adult wards were monitored from 2017-2023, with 38,118 (53.2%) patients on at least one antimicrobial. Overall, 50.8% received at least one antimicrobial for a community-acquired infection, 14.8% for healthcare-associated infections, 24.4% for surgical prophylaxis, and 8.9% for medical prophylaxis. The most commonly used systemic antibiotics for adults were ceftriaxone, piperacillin and enzyme inhibitor, and cefuroxime (Table 1). The most common indication for therapeutic antimicrobial use was pneumonia (Table 2).


The quality indicators monitored included documentation of reason/indication in notes (range: 59.8–81.6%, mean: 73.1%), stop date documentation (range: 29.7– 53.4%, mean: 44.8%), and compliance with treatment guidelines (range: 67.2–85.4%, mean: 79.6%) (Figure 1).

ESCMID Global 2025 (P2646)





Figure 1. Quality Indicators of antimicrobial prescriptions in adult wards (% of prescriptions) 2017-2023



CONCLUSION

Although the network of surveyed hospitals expanded over the years, there has been an overall increase in documentation of reason for antimicrobial use and guideline compliance between 2017 and 2023, but there is still room for improvement. Antimicrobial stewardship programs need to be strengthened further to improve documentation of stop or review dates, thereby facilitating de-escalation where appropriate, and optimising treatment duration.

Key words: Antibiotic stewardship (AMS), Public Health and surveillance, Quality indicators Acknowledgement: Pharmaceutical Division, Department of Health, Philippines

> Disclosures: bioMérieux is the sole industrial partner of the Global-PPS. The company has no role in study design, data collection, data analysis, data interpretation, or writing the report. Data are strictly confidential and stored anonymously at the coordinating centre of the University of Antwerp.

Scan for more info on **Global-PPS**

